Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

ObsEva Announces Year End 2019 Financial Results and Business Update

GlobeNewswire March 5, 2020

ObsEva SA to Hold Year End 2019 Financial Results and Business Update Conference Call on March 5, 2020

GlobeNewswire February 27, 2020

Correction: ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020

GlobeNewswire February 18, 2020

ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020

GlobeNewswire February 18, 2020

ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco

GlobeNewswire January 15, 2020

ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China

GlobeNewswire January 13, 2020

ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020

GlobeNewswire January 7, 2020

ObsEva Announces Third Quarter 2019 Financial Results

GlobeNewswire November 7, 2019

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

GlobeNewswire November 7, 2019

Correction: ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

GlobeNewswire November 6, 2019

ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

GlobeNewswire November 6, 2019

ObsEva SA to Participate in Upcoming Investor Conferences

GlobeNewswire November 6, 2019

ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019

GlobeNewswire November 4, 2019

ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

GlobeNewswire October 31, 2019

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

GlobeNewswire October 11, 2019

ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

GlobeNewswire October 9, 2019

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

GlobeNewswire September 27, 2019

ObsEva announces new composition of its Executive Committee

GlobeNewswire September 11, 2019

ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF

GlobeNewswire September 3, 2019

ObsEva SA to Participate in Upcoming Investor Conferences

GlobeNewswire August 30, 2019